Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Improved Removal of Free Light Chains by Hemodialysis With Medium Cut-Off Dialyzer
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Improved Serum Phosphorous and Small Molecule Removal With Expanded Hemodialysis and Hemodiafiltration vs. Conventional Hemodialysis: A Cross-Over Randomized Clinical Trial
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Improved β2-Microglobulin and Phosphorous Removal with Expanded Hemodialysis and Online Hemodiafiltration versus High-Flux Hemodialysis: A Cross-Over Randomized Clinical Trial
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
In vitro benchmark of cytokine removal by dialyzers with various permeability profiles
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
In Vitro Cytokine Removal: Comparison of Conventional High-Flux Dialyzers and Middle-Cut-Off Dialyzer (Theranova HDx)
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Inflammation and Protein-Energy Wasting in the Uremic Milieu
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Inflammation: A Key Contributor to the Genesis and Progression of Chronic Kidney Disease
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Innovations of renal replacement techniques at the intersection of clinical trial and real-world data.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Intradialytic kinetics of middle molecules during hemodialysis and hemodiafiltration
Visit resource site
HD
Intradialytic kinetics of middle molecules during hemodialysis and hemodiafiltration - Leypoldt et al.
Visit resource site
HD
Is Anticoagulation Discontinuation Achievable with Citrate Dialysate during HDF Sessions? - Dolley-Hitze T et al
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Is Expanded Hemodialysis an Option to Online Hemodiafiltration for Small- and Middle-Sized Molecules Clearance?
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.